Physician profile
Patrick Villafuerte
NPI 1114295722
$7,580.11
in general payments reported to CMS, 2019-2025
16 companies · $1,493 in 2025
The $1,493 reported for 2025 was more than what 83% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $506 · 2020: $181 · 2021: $728 · 2022: $1,343 · 2023: $1,657 · 2024: $1,672 · 2025: $1,493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,797 · Education: $24.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,797.19 |
| Education | $24.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,383.95 | 2019-2025 | Veklury, Epclusa |
| Merck Sharp & Dohme LLC | $994.63 | 2019-2025 | Dificid, Pifeltro, Delstrigo |
| Insmed, INC. | $954.66 | 2020-2025 | Arikayce |
| Melinta Therapeutics, LLC | $765.32 | 2021-2025 | Kimyrsa, Rezzayo, Vabomere |
| Viiv Healthcare Company | $676.48 | 2019-2025 | Cabenuva, Dovato |
| Shionogi INC | $641.37 | 2022-2025 | Fetroja |
| Abbvie INC. | $619.15 | 2022-2025 | Avycaz, Dalvance, Teflaro |
| Paratek Pharmaceuticals, INC. | $532.18 | 2019-2025 | Nuzyra |
| La Jolla Pharmaceutical Company | $395.29 | 2021-2025 | Xerava, Zevtera |
| Ferring Pharmaceuticals INC. | $227.54 | 2022-2025 | Rebyota |
| Aimmune Therapeutics, INC. | $199.54 | 2024-2025 | Vowst |
| Astellas Pharma US INC | $71.51 | 2021-2022 | |
| Allergan, INC. | $42.74 | 2019-2020 | |
| Tetraphase Pharmaceuticals, INC. | $42.44 | 2025 | |
| Vyera Pharmaceuticals, LLC | $17.16 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $16.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Villafuerte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.